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http://www.biomedcentral.com/1471-2407/12/565RESEARCH ARTICLE Open AccessComplement activation in astrocytomas:
deposition of C4d and patient outcome
Katri Mäkelä1,4*, Pauli Helén2, Hannu Haapasalo1,3 and Timo Paavonen1,3Abstract
Background: C4d is a cleavage product of complement component C4 and is considered to serve as a marker for
the site of complement activation. In this study C4d staining of grade I-IV astrocytic tumors was studied to explore
if there is an association between complement activation and the grade of tumor, or patient survival.
Methods: Tissue micro-array samples of 102 astrocytomas were stained immunohistochemically. The material
consisted of 9 pilocytic astrocytomas and 93 grade II-IV astrocytomas, of which 67 were primary resections and 26
recurrent tumors. The intensity of C4d staining as well as extent of C4d and CD34 staining were evaluated. The
intensity of C4d staining was scored semiquantitatively. The extent of the staining was counted morphometrically
with a point counting grid yielding a percent of C4d and CD34 positive area of the sample.
Results: The intensity and extent of C4d staining increased in grade II-IV diffusely infiltrating astrocytoma tumors in
line with the malignancy grade (p = 0.034 and p = 0.016, respectively, Kruskal-Wallis test). However, C4d positive
tumor area percentages were higher in grade I pilocytic astrocytomas than in grade II-IV diffusely infiltrating
astrocytomas (p = 0.041, Mann–Whitney test). There was a significant correlation between CD34 positive and C4d
positive endothelial area fraction in diffusely infiltrating astrocytomas (p < 0.001, Pearson correlation). In these
tumors, the increasing intensity of C4d staining was also associated with worsened patient outcome (p = 0.014,
log-rank test).
Conclusion: The worsening of patient outcome and malignant progression of tumor cells seem to be connected
to microenvironmental changes evoked by chronically activated complement.
Keywords: Astrocytoma, Glioblastoma, C4d, Complement, Inflammation, Survival, ImmunohistochemistryBackground
Astrocytomas are CNS tumors originating from astro-
cytic glial cells or their precursor cells. They can be
divided into four grades according to WHO criteria by
the appearance of cell atypia, mitosis, microvascular pro-
liferation and necrosis [1]. Grade I astrocytomas are
called pilocytic astrocytomas. They are considered be-
nign as they have a clear borderline and are generally
slow growing. The biological background of pilocytic
astrocytomas differs from grade II-IV tumors. Grade II-
IV astrocytomas have a diffuse growing manner and lack
a clear borderline. They are therefore referred to as* Correspondence: katri.s.makela@uta.fi
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reproduction in any medium, provided the ordiffusely infiltrating astrocytomas. These tumors often
renew and proceed into more malignant grades. Glio-
blastoma multiforme is a grade IV astrocytoma, and the
most prevalent form of astrocytic tumors in adult
patients. Microscopically, glioblastomas can be distin-
guished from grade II-III astrocytomas by the occur-
rence of necrosis and microvascular proliferation.
Glioblastomas have a vivid microvascular proliferation
rate and this results often in abnormal, even glomeruloid
microvascular growth patterns. This can sometimes be
seen in pilocytic astrocytomas, as well. Benign pilocytic
astrocytomas may also reoccur, if a remnant has been
left behind during operation. However, they never turn
into grades II-IV.
Complement is an innate component of the immune
system. It can be initiated by three different pathways,
including the classical pathway, lectin pathway and theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nent of activated complement system yields an active en-
zyme that continues the cascade by cleaving the next
zymogen of the cascade into a functioning enzyme. The
follow-through of complement leaves behind inactive
fragments of complement components. C4d is created
when the complement control protein factor I inacti-
vates C4b by cleaving it into C4c and C4d [3]. C4d
remains covalently bound to the activation point. There
is no apparent biological function associated with C4d
alone [4], but due to its covalent binding and relatively
long half-life, it can be considered as an activation mar-
ker of the classical and lectin pathways of complement.
Only the classical and lectin pathways are known to in-
volve C4d, whilst in the alternative pathway there is no
cleavage of the C4 component [5].
C4d has to date been most widely surveyed on allo-
graft tissue rejections. In allograft rejection studies, C4d
positivity has been mainly seen in the cytoplasm of
endothelial cells. Studies concerning tumors have shown
that neoplastic cells and their extracellular matrix can
also stain positive for C4d. For example significant C4d
immunostaining has been reported in tumor cells of
papillary thyroid carcinomas [6] and around neoplastic
follicular dendritic cells in follicular lymphomas [7]. In
the central nervous system (CNS) C4d staining has been
observed in both glial and endothelial cells, but yet to
our knowledge no study has been made to widely exam-
ine the appearance of C4d in astrocytic tumor tissue.
In this study, we examined complement activation in
grade I-IV astrocytomas utilizing C4d immunohisto-
chemistry. The purpose was to compare the appearance
of C4d staining between different grades of astrocytomas
and between primary and secondary resections of these
tumors. Also complement activation on microvessel
endothelium of astrocytomas was examined. One aim
was also to assess via C4d immunopositivity if the extent
of complement activation correlates with patient sur-
vival. Yin et al. have shown that the complement system
activates more easily in stressed endothelial cells than
cells under normal physiological conditions [8]. We
hypothesize that the pathological blood flow caused by
the abnormal microvascular patterns in astrocytic
tumors with vivid microvascular proliferation activate
complement and cause them to stain more strongly by
C4d than astrocytomas with less vivid microvascular
proliferation.
Methods
Study material
The study material consisted of 102 astrocytomas, of
which 9 were grade I pilocytic astrocytomas and 93 were
grade II-IV diffusely infiltrating astrocytomas [grade II
(n = 21), grade III (n = 16) and grade IV (n = 56)]. Of the93 diffusely infiltrating astrocytomas (grades II-IV), 67
were primary tumors and 26 recurrent. First, the astro-
cytoma specimens were fixed in 4% phosphate-buffered
formaldehyde and processed into paraffin blocks. On the
basis of H&E-stained slides, one neuropathologist (H.H.)
evaluated the tumors according to the WHO 2007 cri-
teria [1]. One histologically representative tumor region
was selected from each sample specimen. Thus collected
samples were mounted into multitissue blocks, which
were constructed with a custom made instrument (Bee-
cher Instruments, Silver Spring, MD, USA). The sample
diameter of the tissue cores was 1000 μm. Also samples
representing normal, non-neoplastic brain were included
into blocks to serve as controls.
The samples were obtained from surgically operated
patients at the Tampere University Hospital, Tampere,
Finland, during 1983 to 2001. The tumors were radically
resected if possible and most patients with grade III-IV
astrocytomas also received radiotherapy. Adjuvant radio-
chemotherapy was not used in the period of the study.
Mean patient age was 59 years, the youngest patient
being 12 years old and the oldest 85 years old. Overall
survival was known for 62 patients. Patient survival was
examined in a five year follow-up study. The follow-up
time started after primary resection of the astrocytoma
and ended after five years of follow-up or if the patient
died. The study protocol was approved by the Ethical
Committee of Tampere University Hospital and the Na-
tional Authority for Medicolegal Affairs of Finland.
Immunohistochemistry
Two slides were produced from each multitissue paraffin
block, cut at 5 μm thickness. Fully automated immunos-
taining was performed by a Ventana BenchMark LT
Automated IHC Stainer (The BenchMark Series auto-
mated slide preparation system by Ventana Medical Sys-
tems, Tucson, AZ, USA). Ventana EZ Prep solution
(catalogue No 950–100, Ventana) was used for deparaffi-
niztion. For epitope retrieval CC1: Tris -EDTA buffer
pH 8.0 (catalogue No 950–124,Ventana) was used at
95°C to 100°C for 30 minutes. The slides were rinsed be-
tween steps with Ventana Tris-based Reaction buffer
(catalogue No. 950–300, Ventana). Slides were incubated
at 37°C for 32 minutes with a C4d specific rabbit poly-
clonal anti human C4d antibody (Biomedica Medizin-
produkte GmbH & Co KG, Wien, Austria) using a 1:10
dilution. The staining kit used was the Ventana
Ultraview DAB Detection Kit. A sample of a rejected
kidney allograft served as a positive control for C4d
immunostaining.
To compare the C4d endothelial staining extent with
the overall tumor vascularity, the second slide from each
multitissue block was stained with CD34 antibody. Lyo-
philized mouse monoclonal antibody, specific to the
Figure 1 Moderate diffuse cytoplasmic C4d immunopositivity
in tumor cells of a grade II diffuse astrocytoma. The endothelium
of this tissue sample is negative. Magnification x200.
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Newcastle Upon Tyne, UK) was used as an endothelial
cell marker. The dilution used was 1: 500.
Morphometry
The extent of the staining reaction was determined by
area fractions of the positively stained tumor samples,
using a point counting grid [9]. In this method, the sam-
ple is viewed with a microscope at magnification x400,
and the point counting grid is placed over the tumor
sample and the points covering the sample are counted.
A value was given to each sample using the formula ((Σ
C4d-P)/(Σ Pt)) x 100, where “Σ C4d-P” is the number of
C4d positive points of a tumor sample and “Σ Pt” is the
number of all points of the grid covering the entire
tumor sample. C4d positive tumor area fractions and
C4d positive endothelium area fractions were counted
separately. Necrotic areas were omitted from the
analysis.
The CD34 positive area fraction of the tumor sample
was counted using the same morphometric method as
for the C4d fractions. CD34 was assumed to stain specif-
ically the endothelial cell cytoplasm and therefore the
value acquired from the morphometric count was con-
sidered to represent the percentage of the total micro-
vessel area of the tumor sample.
For further analyses, the tumor samples were scored
for the intensity of C4d positivity with scores from zero
to three (C4d INT). Zero was given if the sample was
negative, one if slightly positive, two if clearly positive
and three if strongly positive. Both endothelial positivity
and tumor cell positivity were taken into account.
The tumor samples were also divided into three
groups according to the extent of the staining reaction
on the grounds of the C4d positive tumor area fraction
(C4d EXT). 1 = no positivity, 2 = 2% or less positive tis-
sue, 3 =more than 2% positive tissue. The tissue sam-
ples were also grouped according to the C4d positive
endothelial area fraction (C4d END). 1 = no positively
stained endothelium was seen, 2 = 0.5% or less of the
tissue area was positively stained endothelium, 3 = more
than 0.5% of the tissue area was positively stained
endothelium.
To statistically compare the C4d endothelial positivity
to overall vascularity of the tumor, a variable was created
in which the percentage of the C4d positive endothelial
area fraction was divided by the CD34 tissue area frac-
tion percentage.
Statistics
The statistical analyses were performed using SPSS for
Windows (Chicago, IL, USA). The significance of asso-
ciations were defined using Kruskal-Wallis test, Mann–
Whitney test and chi-square test. The significance ofcorrelations was determined utilizing Pearson correl-
ation. Kaplan-Meier curves and log-rank test were used
in the survival analyses.
Results
C4d positive staining was seen in endothelial cell
cytoplasm, as well as in astrocytoma cell cytoplasm
and tissue extracellular matrix. Positive staining is
demonstrated in Figures 1, 2, 3. C4d negative normal
brain tissue is demonstrated in Figure 4. Of the 102
astrocytomas (grades I-IV), 76 (74.5%) stained C4d posi-
tive. The C4d positive tumor area fractions of astrocyto-
mas were between 0–84.7%, the mean value being 6.7%.
C4d positive endothelium area fractions were between
0–3.5%, with a mean value of 0.2%. It was a common oc-
currence that tumor cells and endothelial cells simultan-
eously stained strongly.
In the grade II-IV diffusely infiltrating astrocytomas,
the intensity of C4d staining (C4d INT) was found to
correlate with the grade (p = 0.034, Kruskal-Wallis test,
Table 1). The C4d positive tumor area fraction (C4d
EXT) was also found to correlate with the grade of grade
II- IV astrocytomas (p = 0.016, K-W test). Both intensity
(C4d INT) and the C4d positive area fraction (C4d EXT)
were found to increase progressively as the malignancy
of the diffusely infiltrating astrocytoma advanced. The
medians, means and standard deviations for C4d positive
area fractions (C4d EXT) are presented according to the
different grades in Table 2.
There was a difference in the C4d staining between
pilocytic grade I and diffusely infiltrating grade II-IV
astrocytomas. The C4d positive tumor area percentages
were higher in pilocytic tumors of grade I than in grade
II-IV diffusely infiltrating astrocytomas (p = 0.041,
Mann–Whitney test). This statistically significant
Figure 2 Intensively C4d positive tumor cell surrounded by
negatively stained cells in a grade III anaplastic astrocytoma.
Magnification x400.
Figure 4 Normal brain tissue which served as a control in C4d
staining. Brain tissue and endothelium in the capillary are C4d
negative. Magnification x 200.
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The mean of C4d positive tumor area fractions in pilocy-
tic astrocytomas was 18.4%. The second highest positive
tumor area percentages were achieved by the glioblast-
omas with a mean value of 8.2%.
A significant correlation between the CD34 positive
endothelial area fraction and C4d positive endothelial
area fraction was found in the diffusely infiltrating grade
II-IV astrocytomas (r = 0.381, p < 0.001, Pearson Correl-
ation). Figures 3a and 3b demonstrate the simultaneous
C4d and CD34 positive staining of capillaries. As seen in
Table 2, the proportion of C4d positive endothelium to
overall vascularity (C4d / CD34) appears to rise along
with the grade of the tumor, although no significance
was achieved.
A difference in the C4d positivity was found between
primary and recurrent diffusely infiltrating grade II-IV
astrocytomas. Compared to primary tumors, recurrent
tumors had more C4d positive samples in the C4d EXT
variable. In 46% of primary tumors the C4d EXT was
over 0%, whereas 65% of recurrent tumors had an C4d
EXT value over 0%. (p = 0.047, Chi-Square test.).Figure 3 a) C4d positive endothelium. b) CD34 positive endothelium. Th
anaplastic astrocytoma. The sections are adjacent and the same capillariesComparing the other C4d variables between primary
and recurrent tumors, no statistically significant differ-
ences were found.
Survival
In the five year follow-up, the increasing intensity of
C4d staining (C4d INT) in diffusely infiltrating astrocy-
tomas of grades II-IV was associated with patients hav-
ing a worsened outcome (p = 0.014, log-rank test). The
mean lifetime after primary resection for patients in the
C4d INT group 0 was 32.5 months (95% confidence
interval 21.9-43.0), in group 1 the mean lifetime was
29.8 months (CI 21.2-38.3), in group 2 the mean lifetime
was 14.1 months (CI 6.7-21.4) and in group 3 the mean
lifetime was 9.7 months (CI 3.0-16.3). The patient sur-
vival in different C4d intensity groups are presented in
Figure 6. C4d EXT did not correlate significantly with
survival. In addition, Cox multivariate analysis showed
that only WHO grade was an independent prognostica-
tor (Exp(B) 5.666, p < 0.001, 95% confidence interval
3.069 – 10.459). Other parameters included to the multi-
variate analysis were C4d INT, C4d EXT and patient age.e samples are from consecutive sections of the same grade III
are cut in both samples. Magnification x400.
Table 1 Association between C4d staining intensity (C4d
INT) and WHO grade*
Grades Total
Grade I Grade II Grade III Grade IV
C4d intensity 0 1 10 4 11 26
1 3 10 10 26 49
2 3 1 2 16 22
3 2 0 0 3 5
Total 9 21 16 56 102
*(p = 0.034, Kruskal-Wallis test).
Figure 5 Box-plot of C4d positive tumor area fractions (C4d EXT)
in grade I-IV astrocytomas. The C4d EXT groups: 1 = no positivity,
2 = 2% or less positive tissue, 3 =more than 2% positive tissue.
(p = 0.041, Mann–Whitney U-test.).
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The intensity of C4d staining and C4d positive tumor
area fraction were found to correlate with the grade of
grade II-IV diffusely infiltrating astrocytomas. The in-
creasing intensity of C4d staining in diffusely infiltrating
astrocytomas was also associated with a patient’s wor-
sened outcome in univariate survival analysis. Compared
to primary tumors, recurrent tumors had more C4d
positive cases. We also found a correlation between the
CD34 positive area fraction and C4d positive endothelial
area fraction in diffusely infiltrating astrocytoma sam-
ples. Interestingly, our results showed that in pilocytic
grade I astrocytomas, the C4d positive tumor area frac-
tions were higher than in diffusely infiltrating astrocyto-
mas of grade II-IV. This was even though in the
diffusely infiltrating astrocytomas positivity linearly and
significantly followed the WHO grade. Although C4dTable 2 The association of WHO grade to C4d positive
tumor area, C4d positive endothelium, and to the
fraction of C4d positive endothelium
C4d EXT Mean(%) Std.(%) Median(%) p-value
Grade I 18.4 22.5 8.2 0.041*
Grade II 2.1 8.7 0.0
Grade III 0.7 0.9 0.4
Grade IV 8.2 17.3 0.8 0.016**
C4d END
Grade I 0.1 0.1 0.0 n.s.*
Grade II 0.1 0.2 0.0
Grade III 0.3 0.5 0.0
Grade IV 0.3 0.6 0.0 n.s.**
C4d/CD34
Grade I 4.8 12.3 0.0 n.s.*
Grade II 3.0 7.5 0.0
Grade III 12.1 19.1 0.0
Grade IV 20.3 71.3 0.0 n.s.**
C4d EXT = C4d positive tumor area fraction, C4d END = C4d positive
endothelial area fraction, C4d / CD34 = the proportion of C4d positive
endothelial area fraction of the CD34 positive endothelium. p-value; * = Mann–
Whitney U-test between pilocytic (grade I) and diffusely infiltrating (grades II-
IV) astrocytomas; ** = Kruskal-Wallis test between different grades of diffusely
infiltrating (grade II-IV) astrocytomas.intensity was found to be a significant prognosticator in
univariate survival analysis in the present study, it did
not appear as an independent prognostic factor in the
Cox multivariate survival analysis. Reason for this is
probably the close association of the C4d intensity with
the tumor grade, which is found commonly to be the
best prognostic factor of the diffusely infiltrating astrocy-
tomas [1]. In addition, we believe that our material of
primary diffuse astrocytomas is perhaps too small for re-
liable Cox analysis.Figure 6 Patient survival according to C4d staining intensity in
diffusely infiltrating grade II-IV astrocytomas. (p = 0.014, log-rank
test).
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cytic astrocytomas and glioblastomas [1]. One simple
reason to the high C4d expression in these tumors could
be that the abnormally proliferative, leaky blood vessels
elicit inflammatory changes resulting in complement ac-
tivation. Furthermore, the extensive activation of the
complement in abnormal blood vessels may consume
the serum C4 component and this way explain the study
finding of Gousias et al., in which they showed a reduced
serum C4 in patients with grade II-IV glioma and an in-
verse correlation between serum C4 and glioma grade
[10]. However, in the case of pilocytic astrocytomas, the
high C4d positive tumor area fractions could also be
associated with complement inhibiting complement
regulatory proteins (CRPs). There is evidence that be-
nign tumors express CRPs in a much lesser extent than
malignant tumors [11,12]. Thus complement activation
could take place more readily in benign than malignant
tissues due to a lower expression of complement inhibit-
ing CRPs, leading to further emergence of C4d. Al-
though, C4d could also accumulate on pilocytic cell
surfaces, due to longer lifetime of the pilocytic cells
compared to malignant astrocytic tumor cells.
In malignant astrocytomas CRPs have been connected
to the ability to evade immune destruction. According to
Mäenpää et al. malignant glioma cell lines are exception-
ally resistant to complement mediated lysis, mainly
because of the widespread expression of CRPs on their
cell membranes [13]. Glioblastomas can also avoid
complement-mediated killing by the active production
of soluble complement inhibitors factor H and factor
H-like protein 1 [14]. This may be also why glioblast-
omas stain more extensively than grade II and III dif-
fusely infiltrating astrocytomas.
Hanahan and Weinberg have recently nominated the
capability of cancer cells to evade immune destruction
as a hallmark of cancer [15]. In the case of malignant
astrocytic cells, CRPs could be one element that helps
these cells evade immune destruction. Increased C4d in-
tensity at the complement activation site may reflect
thus the ineffectiveness of the immune destruction sys-
tem against cancer cells, which leads to chronic activa-
tion of the complement system. Chronically activated
complement can proceed towards inflammation [16].
Hanahan and Weinberg illustrate in their recent article
that inflammation and genome instability are the enab-
ling characteristics in the acquisition of core cancer hall-
mark capabilities, allowing cancer cells to survive,
proliferate and disseminate [15]. Cytokines, free radicals,
prostaglandins and growth factors are a part of the acti-
vated inflammatory complex. They can cause alterations
in the creation of DNA mutations in tumor suppressor
genes and failure in normal protein synthesis, causing
defects in the function of the cell, leading to progressionof cancer [17,18]. Understandably all this can lead to
worsened patient outcome.
The univariate survival study results, which showed
that a worsened outcome is associated with intensified
complement activation in grade II-IV astrocytomas, can
thus reflect the effect of the pathological microenviron-
ment provided by inflammation. Also, since the inflam-
matory microenvironment allows cancer cells to survive,
proliferate and make the cell genome unstable, it is pos-
sible that the inflammatory microenvironment could
also enhance the recurrence of tumors after primary re-
section. In our study, recurrent diffusely infiltrating
astrocytomas had more C4d positive cases than primar-
ily resected ones, supporting this supposition.
Conclusion
This study shows that the intensity of complement acti-
vation, detected by C4d positive staining, is associated
with the grade of grade II-IV diffusely infiltrating astro-
cytomas and the primarity of resection. There is also an
association between complement activation and the
prognosis of patients suffering from diffusely infiltrating
astrocytomas. The worsening of outcome can be con-
nected to the microenvironment changes, which are
caused by the inflammatory mediators evoked by com-
plement activation.
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